XLO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

10.90M

+532.25%

-0.070

-65%

6.90M

+135.49%

-0.105

-41.67%

6.00M

-25.78%

-0.105

-34.38%

Estimates Revision

The market is revising Upward the revenue expectations for Xilio Therapeutics, Inc. (XLO) for FY2025, with the revenue forecasts being adjusted by 5.37% over the past three months. During the same period, the stock price has changed by -12.97%.

Revenue Estimates for FY2025

Revise Upward

+5.37%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-5.38%

In Past 3 Month

Stock Price

Go Down

-12.97%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast XLO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XLO is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.654

Low

2.00

Averages

2.00

High

2.00

Current: 0.654

Low

2.00

Averages

2.00

High

2.00

Leerink

Outperform

initiated

$72

2025-08-06

Reason

Leerink

Price Target

$72

2025-08-06

initiated

Outperform

Reason

Leerink initiated coverage of Xilio Therapeutics with an Outperform rating and $72 price target. The company's lead program vilastobart, a conditionally masked CTLA-4 antagonist, has shown proof-of-concept efficacy in relapsed / refractory microsatellite stable non-liver metastatic colorectal cancer, a large indication, the analyst tells investors in a research note. The firm believes Xilio is among the industry leaders of developing protease-masked biologics.

Valuation Metrics

The current forward P/E ratio for Xilio Therapeutics Inc (XLO.O) is -1.24, compared to its 5-year average forward P/E of -1.38. For a more detailed relative valuation and DCF analysis to assess Xilio Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.38

Current PE

-1.24

Overvalued PE

-0.27

Undervalued PE

-2.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.18

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.52

Undervalued EV/EBITDA

-1.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.19

Current PS

1.37

Overvalued PS

2.97

Undervalued PS

-0.58

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

XLO News & Events

Events Timeline

No data

News

9.5

11-13NASDAQ.COM

Xilio Therapeutics, Inc. (XLO) Announces Q3 Loss and Falls Short of Revenue Projections

9.0

11-07Newsfilter

Xilio Therapeutics Unveils Late-Breaking Phase 2 Results for Vilastobart in MSS mCRC Patients with Elevated Plasma Tumor Mutational Burden at the 40th Annual SITC Meeting

9.0

10-30Newsfilter

Xilio Therapeutics to Showcase Phase 2 Data on Vilastobart's Response Rate in MSS mCRC Patients with High Plasma Tumor Mutational Burden in Late-Breaking Presentation at SITC 40th Annual Meeting

People Also Watch

Frequently Asked Questions

What is Xilio Therapeutics Inc (XLO) stock price today?

The current price of XLO is 0.6542 USD — it has decreased -3.96 % in the last trading day.

What is Xilio Therapeutics Inc (XLO)'s business?

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. It is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.

What is the price predicton of XLO Stock?

What is Xilio Therapeutics Inc (XLO)'s revenue for the last quarter?

Xilio Therapeutics Inc revenue for the last quarter amounts to 19.07M USD, increased 742.51 % YoY.

What is Xilio Therapeutics Inc (XLO)'s earnings per share (EPS) for the last quarter?

Xilio Therapeutics Inc. EPS for the last quarter amounts to -0.11 USD, decreased -50.00 % YoY.

What changes have occurred in the market's expectations for Xilio Therapeutics Inc (XLO)'s fundamentals?

How many employees does Xilio Therapeutics Inc (XLO). have?

Xilio Therapeutics Inc (XLO) has 64 emplpoyees as of December 15 2025.

What is Xilio Therapeutics Inc (XLO) market cap?

Today XLO has the market capitalization of 35.76M USD.